Skip to main content
NIPH logo

Kohortstudie om varigheten av BCG-vaksinens beskyttelse

Project

|

Last update

Tuberculosis (TB) remains a major preventable cause of morbidity. Bacillus Calmette Guerin (BCG) vaccines are widely used to protect against TB. Their efficacy shortly after vaccination has been demonstrated, but the duration of protection is not wel

Summary

Tuberculosis (TB) remains a major preventable cause of morbidity. Bacillus Calmette Guerin (BCG) vaccines are widely used to protect against TB. Their efficacy shortly after vaccination has been demonstrated, but the duration of protection is not well known. This information is needed to inform BCG vaccination policies and can help to assess the cost of BCG vaccination against its effectiveness in the society. This study will measure the duration of BCG protection against TB and estimate changes in efficacy with time since vaccination. We will use historical population data to compare the frequency of TB occurrence in people who received the BCG and those who did not, at various period after vaccination.

Project leader

Einar Heldal, Norwegian Institute of Public Health

Project participants

Einar Heldal, Infection Control and Vaccines, Norwegian Institute of Public Health

Start

01.04.2012

End

30.12.2023

Status

Concluded

Approvals

Regional committees for medical and health research ethics

Project owner/ Project manager

Norwegian Institute of Public Health

Published |Last update